- Why Research
- Our Impact
- Get Involved
- About BCRF
- Contact Us
- Cancer Divides. We Unite.
You are here
Charles Loprinzi, MD
Regis Professor of Breast Cancer Research
Seeking to improve quality of life for breast cancer patients, with a particular focus on reducing or avoiding treatment-related side effects.
A clinical trial is planned to test an FDA-approved drug to treat overactive bladder for its affect on decreasing hot flashes in women receiving anti-estrogen therapy.
This study could provide new options for patients on hormone therapy struggling with hot flashes, a common side effect of this therapy.
Anti-estrogen therapies, such as tamoxifen and aromatase inhibitors, are often prescribed to prevent breast cancer reccurrence. While these treatments have been clinically proven to reduce the risk of recurrence, they also come with side effects that make them intolerable for some women.
Dr. Loprinzi is conducting a trial that addresses one of the most common symptoms for many breast cancer survivors on anti-estrogen therapy: hot flashes.
In previous trials led by Dr. Loprinzi, the following seven drugs were shown to be helpful for diminishing hot flashes: clonidine, fluoxetine, citalopram, venlafaxine, pregabalin, megestrol acetate, and medroxyprogesterone acetate. Although these agents provide real treatment options, each of them has limitations. Additionally, previous trials determined that black cohosh, magnesium oxide, flaxseed, vitamin E, and soy were not helpful for diminishing hot flashes.
This year he will test whether oxybutynin, an available oral drug for overactive bladder symptoms, will be effective treatment for managing hot flashes in breast cancer patients. He expects to report trial results by the end of 2018.
Dr. Loprinzi is currently the Regis Professor of Breast Cancer Research at the Mayo Clinic, Rochester, MN where he is an emeritus chair of the Division of Medical Oncology and an emeritus Vice-Chair of the Department of Oncology.
He has run an active cancer control program directed toward both cancer prevention efforts and symptom control efforts, which has led to the publication of over 300 articles and book chapters, with over 100 publications in the Journal of Clinical Oncology.
Dr. Loprinzi served as the founding editor for the Art of Oncology section of the Journal of Clinical Oncology from 2000 through 2010. In addition, he edited two anthologies of articles from the Art of Oncology series that are available via the Kindle electronic book format.
His work has lead to him receiving two awards from the Susan G. Komen Foundation: the Komen Foundation Brinker award in 2002 and the 2005 Komen Foundation Professor of Survivorship. In 2005, he was awarded the 2006 Clinical Research Award by the Association of Community Cancer Centers (ACCC). In 2006, he was awarded the North American Menopausal Society (NAMS) Vasomotor Symptoms Research Award.
BCRF Investigator Since